Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

2.

Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study.

Rückert IM, Heier M, Rathmann W, Baumeister SE, Döring A, Meisinger C.

PLoS One. 2011;6(8):e22932. doi: 10.1371/journal.pone.0022932. Epub 2011 Aug 5.

3.

Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.

Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS.

Diabetes Res Clin Pract. 2009 Apr;84(1):84-91. doi: 10.1016/j.diabres.2008.11.039. Epub 2009 Jan 24.

PMID:
19168251
4.

Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey.

Kotronen A, Yki-Järvinen H, Männistö S, Saarikoski L, Korpi-Hyövälti E, Oksa H, Saltevo J, Saaristo T, Sundvall J, Tuomilehto J, Peltonen M.

BMC Public Health. 2010 May 10;10:237. doi: 10.1186/1471-2458-10-237.

5.

Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease.

Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, Sendo R, Mizuno M, Okanoue T.

Hepatol Res. 2015 May;45(5):548-59. doi: 10.1111/hepr.12384. Epub 2014 Aug 13.

PMID:
24976563
6.

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.

Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, Sung JJ, Chan HL.

Aliment Pharmacol Ther. 2006 Oct 15;24(8):1215-22.

7.

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.

Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K, Somogyi A.

PLoS One. 2010 Aug 18;5(8):e12226. doi: 10.1371/journal.pone.0012226.

8.

Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease.

Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI.

Liver Int. 2009 Apr;29(4):525-9. doi: 10.1111/j.1478-3231.2008.01920.x.

9.

Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome.

Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A.

Hepatol Res. 2014 May;44(5):515-22. doi: 10.1111/hepr.12146. Epub 2013 May 22.

PMID:
23617326
10.

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Musso G, Cassader M, Rosina F, Gambino R.

Diabetologia. 2012 Apr;55(4):885-904. doi: 10.1007/s00125-011-2446-4. Epub 2012 Jan 27. Review.

PMID:
22278337
11.

Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).

Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K.

Diabetes Care. 2012 Apr;35(4):873-8. doi: 10.2337/dc11-1849. Epub 2012 Feb 28.

12.

Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.

Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K.

Scand J Gastroenterol. 2005 Dec;40(12):1469-77.

PMID:
16293559
13.

Interaction of type 2 diabetes and nonalcoholic fatty liver disease.

Verderese JP, Younossi Z.

Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):405-7. doi: 10.1586/17474124.2013.811047.

PMID:
23899279
14.

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults.

Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T.

Diabet Med. 2005 Sep;22(9):1141-5.

PMID:
16108839
15.

Lifestyle intervention in individuals with normal versus impaired glucose tolerance.

Schäfer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F, Machicao F, Häring HU, Fritsche A, Stefan N.

Eur J Clin Invest. 2007 Jul;37(7):535-43.

PMID:
17576204
16.

Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes.

Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ.

Clin Endocrinol (Oxf). 2011 Oct;75(4):450-5. doi: 10.1111/j.1365-2265.2011.04070.x.

PMID:
21521338
17.

Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).

Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM.

Dig Dis Sci. 2013 Oct;58(10):3017-23. doi: 10.1007/s10620-013-2743-5. Epub 2013 Jun 18.

PMID:
23775317
18.

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.

Unwin N, Shaw J, Zimmet P, Alberti KG.

Diabet Med. 2002 Sep;19(9):708-23. Review.

PMID:
12207806
19.

Non-alcoholic fatty liver disease: need for a balanced nutritional source.

Veena J, Muragundla A, Sidgiddi S, Subramaniam S.

Br J Nutr. 2014 Dec 14;112(11):1858-72. doi: 10.1017/S0007114514002591. Epub 2014 Oct 2. Review.

PMID:
25274101
20.

Non-alcoholic fatty liver disease: a diabetologist's perspective.

Pappachan JM, Antonio FA, Edavalath M, Mukherjee A.

Endocrine. 2014 Apr;45(3):344-53. doi: 10.1007/s12020-013-0087-8. Epub 2013 Nov 28. Review.

PMID:
24287794

Supplemental Content

Support Center